US6506902B2 - Synthesis of thiazolium compounds - Google Patents
Synthesis of thiazolium compounds Download PDFInfo
- Publication number
- US6506902B2 US6506902B2 US09/821,846 US82184601A US6506902B2 US 6506902 B2 US6506902 B2 US 6506902B2 US 82184601 A US82184601 A US 82184601A US 6506902 B2 US6506902 B2 US 6506902B2
- Authority
- US
- United States
- Prior art keywords
- mixture
- solvent
- product
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *CC(=O)C1=CC=CC=C1.CC.CC.CC Chemical compound *CC(=O)C1=CC=CC=C1.CC.CC.CC 0.000 description 7
- TYOJTNNHWZAKDC-UHFFFAOYSA-N C.CC.CC.CC.CC1=C(C)[N+](CC(=O)C2=CC=CC=C2)=CS1 Chemical compound C.CC.CC.CC.CC1=C(C)[N+](CC(=O)C2=CC=CC=C2)=CS1 TYOJTNNHWZAKDC-UHFFFAOYSA-N 0.000 description 3
- LUYWFIWUDKPIDS-UHFFFAOYSA-N CC1=C(C)SC=N1.II Chemical compound CC1=C(C)SC=N1.II LUYWFIWUDKPIDS-UHFFFAOYSA-N 0.000 description 3
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Definitions
- the present invention relates to methods of synthesizing certain thiazolium compounds.
- the invention provides a method of synthesizing a compound of formula I,
- R 1 and R 2 are independently hydrogen, hydroxy(C 1 -C 2 )alkyl, or (C 1 -C 2 )alkyl with, a compound of the formula III
- R 3 , R 4 , and R 5 are each independently of each other hydrogen, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, or halogen; and X is a leaving group.
- the reaction is preferably conducted in a solvent having a dielectric constant at 20° C. of at least 30 but no more than 40
- the invention provides a method of synthesizing a 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-thiazolium salt comprising: reacting 4,5-dimethylthiazole with (IV), wherein X is a leaving group.
- FIGS. 1 and 2 show HPLC analyses of product made according to the invention.
- reaction and purification conditions have been developed that allow the preparation of N-alkyl thiazolium salts in high yield and of high purity.
- Useful methods described, for example, relate to the preparation of compounds of the formula I by reacting a compound of formula II with a compound of the formula III wherein X is a leaving group.
- the solvent is selected to meet the characteristics described above, allowing the improved yields that can be obtained through the invention. Washing methods with appropriate solvents can also be selected to yield N-alkyl thiazolium salts with surprising purity from simple purification steps.
- the leaving group referred to above preferably form a pharmaceutically or biologically acceptable anion upon alkylation of the thiazole moiety.
- Such anions include, for example, halides, for example, chlorides and bromides, tosylates, methanesulfonates, and mesitylenesulfonates.
- Other related leaving groups that are used preferably are those that form stable, non-toxic, and biologically or pharmaceutically acceptable salts upon alkylation of the thiazole moiety.
- the solvents referred to above are dipolar solvents. These may include, for example, protic solvents, such as C 2 -C 3 alcohols, and aprotic solvents, such as N-methylpyrrolidinone, dimethylformamide, dimethylacetamide, dimethyl sulfoxide, and acetonitrile. Solvents with dielectric constants at 20° C. above 30 but no more than 40 are preferred. Aprotic solvents are also preferred.
- a solvent is selected so that the product thiazolium salt is only partially soluble.
- a solvent in which both the reactants are soluble but in which the thiazolium salt product is insoluble or only partially soluble is preferred.
- Acetonitrile is a preferred solvent.
- the reaction is conducted at elevated temperatures such as 80° C. to 82° C.
- a preferred solvent is one that has a boiling point from 65° C. to 110° C. so that the reaction temperature can be conveniently and consistently maintained by refluxing the solvent. If the reaction mixture is refluxed a condenser should be used during the reaction.
- the reaction is maintained at elevated temperatures for at least 24 hours. Preferably the temperature is maintained for at least 48 to 72 hours or from 80 to 100 hours, e.g. about 90 or 90.5 hours. The length of time will be dependent upon a number of factors, including temperature, concentration, and solvent.
- molar ratios of substituted acetophenone reagents/thiazoles combined in the reaction mixture are about 1:1 to 3:1. In some embodiments, ratios of about 1.5:1 to 2.5:1 (such as about 2:1) are useful.
- a preferred method of conducting the reaction uses an inert atmosphere, for example using a blanket of nitrogen or argon gas. Additionally, the reaction is stirred or agitated using, for example, a mechanical stirring device.
- Reaction progress can be followed by methods known to those in the art including chromatographic methods such as thin layer chromatography or HPLC.
- chromatographic methods such as thin layer chromatography or HPLC.
- HPLC high-density liquid phase chromatography
- a specialized procedure for sampling the reaction mixture can be used.
- a slurry of the hot reaction mixture is filtered and the precipitate and/or filtrate are monitored by one of the chromatographic methods described above or, the slurry is dissolved in a stronger solvent and analyzed chromatographically.
- a preferred method is HPLC analysis when the reaction solvent used does not absorb a detecting-interfering amount of UV light at wavelengths where the products and reactants are detected.
- reaction mixture is cooled, for example, to a temperature of about 15° C. to 30° C., such as 22° C. to 25° C. Then, for example, an ethereal solvent is added, and the reaction product recovered by centrifugation or filtration.
- a preferred ethereal solvent is methyl tert-butyl ether.
- the purification of the reaction product can include a recrystallization step.
- the process of selecting a suitable recrystallization solvent(s) is known to those in the art.
- a solvent is chosen by consideration of a number of factors including maximization of the amount of purified, crystallized product when the crystallization mixture is cooled, and satisfactory solubility of the crude reaction product with the heated recrystallization solvent.
- Suitable recrystallization solvents include, for example, C 1 -C 3 alcohols. 1:1 2:1,
- wash solution would optimally dissolve maximal amounts of impurities while dissolving a minimal amount of the desired reaction product.
- a wash solution could be prepared from variable mixtures of two or more solvents.
- the wash solution can be, for example, a mixture of a C 1 -C 3 alcohol and a C 3 -C 5 ether.
- a preferred wash solution is a mixture of ethanol and methyl tert-butyl ether.
- the mixture of ethanol and ether is preferably a 2:8 to 4:6 (v/v) mixture and more preferably, a 25:75 to 35:65 (v/v) mixture.
- the washing step can be performed after recovery of the reaction product on a filter.
- the washing cycle can be repeated, for example to achieve a higher purity of the product.
- the purity of the reaction product from the washing steps is at least 99.5% by isocratic reversed-phase HPLC analysis at 210 nm, preferably at least 99.7% or 99.8%.
- the washing step can further comprise suspending the reaction product in the washing solvent, agitating the resulting slurry, and recovering the product by filtration.
- the slurry is agitated at about 20° C. to 25° C.
- the methods for isolation of the product described in the invention include drying steps.
- the compound can be, for example, dried at room temperature under vacuum, on trays lined with dryer paper.
- Analytical methods for determining the purity of reaction product are known in the art. These include spectroscopic methods, for example, NMR spectroscopy and chromatographic methods.
- a preferred method of determining the purity of the product thiazolium salt is by application of HPLC techniques. While satisfactory analytical HPLC can be performed under a variety of conditions, preferred conditions include using a column with reversed phase packing such as 5 ⁇ ODS-2 (C-18) packing. For example, the 4.6 ⁇ 250 mm 5 ⁇ ODS-2 column from Metachem Technologies (Torrance, Calif.).
- an isocratic solvent system is used to elute the sample, for example, a mobile phase containing 65% of an aqueous buffer of 10 mM 1-nonane sulfonic acid sodium salt and 50 mM sodium phosphate monobasic and 35% acetonitrile.
- the HPLC chromatogram is generated, for example, using a UV detector.
- Typical settings for analysis of the product thiazolium salt include monitoring at 210 nm or 252 nm.
- HPLC data is collected with data sampling at least as frequent as every 0.1 second periods.
- the data is zeroed against a baseline run of the HPLC apparatus.
- Sensitivity or peak detection threshold is preferably set to a high sensitivity value that nonetheless allows data collection without spurious collection of detector or electronic noise. For example, using Rainin Dynamax R software (version 1.4) to collect the data, and Rainin Dynamax Mode UV-1 UV/visible variable wavelength detector, minimum peak detection sensitivity can be set at 10-50 millivolt/second or lower.
- FIG. 1 shows an analysis of a batch of 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-thiazolium chloride as analyzed by a gradient HPLC method that uses a 25 to 50% acetonitrile gradient.
- FIG. 2 shows an isocratic analysis (35% acetonitrile, v/v). HPLC chromatographs were developed in 50 mM NaH 2 PO 4 , 10 mM 1-nonane sulfonic acid Detection was at 210 nm.
- the yield of the product from the above conditions is high (e.g. 70% overall, or higher).
- the product can be obtained at high purity using the methods here described (>99.5% as determined by HPLC). Additionally, the process is convenient for preparing thiazolium salts on a commercial scale.
- a reactor equipped with an agitator and a condenser was charged with 37.47 kg of acetonitrile, and purged with nitrogen. A blanket of nitrogen was maintained during the reaction. Agitation was started and 9.52 kg of 4,5-dimethylthiazole (84.1 mmol) and 13.00 kg of 2-chloroacetophenone (84.1 mmol) were added into the reactor. The mixture was agitated and heated to reflux (81° C.). Refluxing was maintained at this temperature for about 96.5 hours. The reaction was monitored by HPLC for the presence of 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-thiazolium chloride in the refluxate. The product precipitated out of the hot reaction mixture during reflux. After 3 days a sample of hot reaction slurry was filtered, and washed with a mixture of absolute ethanol and methyl tert-butyl ether (3:7). An HPLC analysis of this sample showed no detectable amounts of starting materials.
- the reaction was cooled to 20° C. to 25° C. and 33.7 kg of methyl tert-butyl ether was added.
- the batch was agitated at 20° C. to 25° C. for about 3 hours.
- Part of the mixture was isolated in the centrifuge; the remaining product was agitated overnight and was isolated by filtering through a large buchner funnel fitted with Whatman # 1 filter paper.
- the product from the centrifuge was transferred to the top of the cake in the buchner funnel.
- the reactor (R-2) was rinsed with 20 L of methyl tert-butyl ether onto the product cake.
- the filtered cake was washed three times with a wash solution containing a mixture of 4.17 kg of absolute ethanol and 9.74 kg of methyl tert-butyl ether.
- the wet solid (20.07 kg) was transferred to the drying trays.
- the product was evenly distributed on the trays and dried at room temperature under vacuum (25.6′′ Hg) for 18 hours.
- the dry weight of the 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-thiazolium chloride was 17.99 kg.
- Crude 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-thiazolium chloride was recrystallized by charging the crude 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-thiazolium chloride into a reactor equipped with a condenser and an agitator. Absolute ethanol 37.19 kg was added and agitation was started. The reactor was purged with nitrogen and a nitrogen blanket was maintained during the processing. The mixture was heated to gentle reflux and maintained at 78° C. until a complete solution was attained. From the bottom outlet of the reactor to the inlet of another reactor, a 0.5 micron in-line cartridge filter was set up using an appropriate pump.
- the filter cartridge, pump, and lines were preheated with the hot absolute ethanol in the first reactor.
- the batch was filtered into the new reactor.
- Absolute ethanol (4.2 kg) was used to rinse the first reactor into the reactor containing the filtrate.
- the batch was cooled to 20° C. to 25° C. and agitated at this temperature overnight.
- the product was filtered through a large Buchner funnel fitted with a Whatman No. 1 filter paper.
- the filtered cake was washed with a wash solution containing a mixture of 5.80 kg of absolute ethanol and 13.52 kg of methyl tert-butyl ether.
- Methyl tert-butyl ether 18.9 kg and absolute ethanol 8.0 kg were added to a reactor equipped with a condenser and an agitator.
- the reactor was purged with nitrogen and a nitrogen blanket was maintained during the processing.
- 4,5-Dimethyl-3-(2-oxo-2-phenylethyl)-thiazolium chloride (Lot. A) 11.9 kg was charged into the reactor and the agitator started.
- the slurry was stirred at 20° C. to 25° C. for about 30 minutes.
- the product was filtered through a large buchner funnel fitted with a Whatman No. 1 filter paper.
- the filtered cake was washed with a wash solution containing a mixture of 1.3 kg of absolute ethanol and 3.2 kg of methyl tert-butyl ether.
- the wet 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-thiazolium chloride (13.4 kg) was transferred to the trays lined with dryer paper. The product was distributed evenly on the trays.
- 4,5-Dimethyl-3-(2-oxo-2-phenylethyl)-thiazolium chloride was dried at room temperature under vacuum (25.9′′ Hg) about 2 hours to a constant weight.
- the dryer was unloaded into a tared, polyethylene bag-lined drum or pail. (11.8 kg, 99.2% from Lot No. A; 52.40% overall yield (Lot No. B).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (29)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/821,846 US6506902B2 (en) | 2000-03-29 | 2001-03-29 | Synthesis of thiazolium compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19286700P | 2000-03-29 | 2000-03-29 | |
US09/821,846 US6506902B2 (en) | 2000-03-29 | 2001-03-29 | Synthesis of thiazolium compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
US20020013471A1 US20020013471A1 (en) | 2002-01-31 |
US6506902B2 true US6506902B2 (en) | 2003-01-14 |
Family
ID=22711353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/821,846 Expired - Fee Related US6506902B2 (en) | 2000-03-29 | 2001-03-29 | Synthesis of thiazolium compounds |
Country Status (3)
Country | Link |
---|---|
US (1) | US6506902B2 (en) |
AU (1) | AU2001249683A1 (en) |
WO (1) | WO2001072724A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040034074A1 (en) * | 1995-01-18 | 2004-02-19 | Anthony Cerami | Preventing and reversing the formation of advance glycosylation endproducts |
WO2015051218A1 (en) | 2013-10-04 | 2015-04-09 | The Procter & Gamble Company | Process and apparatus for making tufted article |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5656261A (en) * | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
US5853703A (en) * | 1995-01-18 | 1998-12-29 | The Picower Institute For Medical Research | Preventing and reversing the formation of advanced glycosylation endproducts |
-
2001
- 2001-03-29 US US09/821,846 patent/US6506902B2/en not_active Expired - Fee Related
- 2001-03-29 WO PCT/US2001/010355 patent/WO2001072724A1/en active Application Filing
- 2001-03-29 AU AU2001249683A patent/AU2001249683A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5656261A (en) * | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
US5853703A (en) * | 1995-01-18 | 1998-12-29 | The Picower Institute For Medical Research | Preventing and reversing the formation of advanced glycosylation endproducts |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040034074A1 (en) * | 1995-01-18 | 2004-02-19 | Anthony Cerami | Preventing and reversing the formation of advance glycosylation endproducts |
US7022719B2 (en) * | 1995-01-18 | 2006-04-04 | Alteon, Inc. | Preventing and reversing the formation of advance glycosylation endproducts |
US20070025926A1 (en) * | 1995-01-18 | 2007-02-01 | Anthony Cerami | Preventing and reversing the formation of advance glycosylation endproducts |
US20080132553A1 (en) * | 1995-01-18 | 2008-06-05 | Anthony Cerami | Preventing and reversing the formation of advance glycosylation endproducts |
WO2015051218A1 (en) | 2013-10-04 | 2015-04-09 | The Procter & Gamble Company | Process and apparatus for making tufted article |
Also Published As
Publication number | Publication date |
---|---|
US20020013471A1 (en) | 2002-01-31 |
AU2001249683A1 (en) | 2001-10-08 |
WO2001072724A1 (en) | 2001-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2430092C2 (en) | Method of producing telmisartan | |
KR101731739B1 (en) | Process for the preparation of (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and intermediate used in said process | |
WO2019232138A1 (en) | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide | |
SK280520B6 (en) | Method for preparing 4-acetoxy-2alpha-benzoyloxy-5alpha,20- -epoxy-1,7beta,10beta-trihydroxy-9-oxo-tax-11-en-13alpha- -yl(2r,3s)-3-tert-butoxycarbonylamino-2-hydroxy-3- -phenylpropionate trihydrate | |
EA020473B1 (en) | PURIFICATION OF 1-[2-(2,4-DIMETHYLPHENYLSULFANYL)PHENYL]PIPERAZINE-HBr | |
CZ281893B6 (en) | Process for preparing arylpiperazinyl heterocyclic compounds | |
CN111233870A (en) | Method for rapidly preparing Rudeseivir drug intermediate | |
CA2606958A1 (en) | Synthesis of anastrozole and purification of one of its intermediate | |
US6506902B2 (en) | Synthesis of thiazolium compounds | |
EP0976750A1 (en) | Novel z-valacyclovir crystals | |
CA2176181C (en) | D4t polymorphic form i process | |
US8178674B2 (en) | Process for the preparation of ziprasidone | |
CN115960059A (en) | Method for synthesizing furosemide impurity D with high yield and high purity | |
FR2534256A1 (en) | ||
IL168452A (en) | Process for preparing substituted imidazole derivatives and intermediates used in the process | |
US3872082A (en) | Substituted purineribofuranoside-3,5-cyclophosphate compounds and process for their preparation | |
US4876337A (en) | Method and apparatus for the preparation of cyanoalkyl-alkoxysilanes | |
KR20070033317A (en) | Novel Polymorphs of Atobaquion and Methods for Making the Same | |
CN110396066B (en) | 1- (3, 5-dimethoxy phenyl) -3-substituted urea colon cancer inhibitor and preparation and application thereof | |
US20040267023A1 (en) | Novel process for the preparation of the insulin sensitizer | |
KR880000154B1 (en) | The method of preparation for amino-nitro pyridine | |
US6333414B1 (en) | Process for the synthesis of trisubstituted oxazoles | |
JP2002155058A (en) | Method for producing 1-substituted hydratoin compound | |
JPH1029981A (en) | Production of hexahydropyridazine compound | |
CN116162036A (en) | Preparation method of epinephrine impurity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALTEON, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WAGLE, DILIP;REEL/FRAME:012667/0832 Effective date: 20010714 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: BAKER BROS ADVISORS, LLC, AS COLLATERAL AGENT FOR Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:ALTEON INC., A DELAWARE CORPORATION;REEL/FRAME:018746/0676 Effective date: 20070111 |
|
AS | Assignment |
Owner name: SYNVISTA THERAPEUTICS, INC., NEW JERSEY Free format text: RELEASE OF SECURITY INTEREST (REEL/FRAME 018746/0676);ASSIGNOR:BAKER BROS ADVISORS, LLC;REEL/FRAME:019658/0176 Effective date: 20070725 |
|
AS | Assignment |
Owner name: SYNVISTA THERAPEUTICS, INC., NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:ALTEON, INC.;REEL/FRAME:019920/0649 Effective date: 20070724 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20110114 |